Source comparison
CJC-1295 No DAC & Ipamorelin vs Other Peptides
A 2019 study published in the Journal of Clinical Endocrinology found that synthetic growth hormone-releasing peptides (GHRPs) can elevate plasma GH levels by 300–800% above baseline depending on the peptide class, receptor selectivity, and dosing protocol. Bu
This comparison does not assign a generated winner or score.
- A 2019 study published in the Journal of Clinical Endocrinology found that synthetic growth hormone-releasing peptides (GHRPs) can elevate plasma GH levels by 300–800% above baseline depending on the peptide class, receptor selectivity, and dosing protocol. But not all peptides produce the same downstream metabolic effects. CJC-1295 No DAC combined with ipamorelin has become the reference standard in research protocols specifically because it delivers sustained GH pulses without the cortisol and prolactin elevation seen with GHRP-2 or the desensitisation risk associated with continuous GH secretagogues like MK-677.
- Our team has worked with researchers across multiple institutions using peptide stacks in metabolic and recovery studies. The gap between doing peptide research correctly and generating inconclusive data comes down to understanding receptor selectivity, half-life profiles, and how different peptides interact when stacked. Details most commercial peptide guides ignore entirely.
- How does CJC-1295 No DAC & ipamorelin compare to other research peptides?
- CJC-1295 No DAC (a GHRH analogue) and ipamorelin (a selective ghrelin receptor agonist) work synergistically to amplify natural GH pulses. CJC extends pulse duration while ipamorelin increases pulse amplitude. This combination produces 200–400% GH elevation with a half-life of approximately 30 minutes for ipamorelin and 6–8 days for CJC-1295 No DAC, creating a sustained but pulsatile release pattern that mirrors endogenous secretion. Comparatively, GHRP-2 elevates GH but also increases cortisol and prolactin by 20–40%, MK-677 (ibutamoren) produces continuous GH elevation with appetite stimulation and potential insulin resistance over time, and hexarelin shows the highest acute GH spike but rapid desensitisation after 14–21 days of use.
- The commercial peptide market often treats all GH secretagogues as interchangeable. They're not. CJC-1295 No DAC with ipamorelin produces a fundamentally different hormonal profile than GHRP-6, hexarelin, or MK-677. And the mechanistic distinctions determine which research outcomes are even possible. This article covers receptor-level selectivity differences, comparative half-life kinetics, stacking synergy versus single-peptide protocols, practical reconstitution and dosing considerations specific to each compound class, and the scenarios where one peptide clearly outperforms another based on study endpoint design.